HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

One-year results of reduced fluence photodynamic therapy for central serous chorioretinopathy: the outer nuclear layer thickness is associated with visual prognosis.

AbstractPURPOSE:
To evaluate the efficacy of reduced-fluence photodynamic therapy (RFPDT) for central serous chorioretinopathy (CSC).
METHODS:
This retrospective medical record review of consecutive CSC patients treated with RFPDT (full-dose verteporfin and laser fluence of 25 J/cm(2)) examined 22 eyes of 21 patients (20 males and one female). All patients were followed-up for 1 year. Best-corrected visual acuity (BCVA), complete resolution of subretinal fluid (CR of SRF), central retinal thickness (CRT), the outer nuclear layer (ONL) thickness, and the photoreceptor inner and outer segments (IS/OS) line determined by optical coherence tomography imaging were evaluated at baseline, 1, 3, 6, 9, and 12 months after initial RFPDT.
RESULTS:
A single RFPDT session was performed in all cases during a 12-month period. CR of SRF was identified in all patients. BCVA significantly improved between 3 and 12 months (P < 0.05). The CRT significantly decreased between 1 and 12 months. A significantly thicker ONL was observed at 1 month, and 17 eyes (77.2 %) showed recovery of the continuous foveal IS/OS line. ONL thickness was correlated with BCVA at 12 months (P < 0.01). Stepwise analysis indicated that pre-treatment BCVA (P < 0.01) and ONL thickness (P < 0.01) were significant predictive factors for BCVA at 12 months. Neither ocular nor systemic adverse effects were observed during the follow-up period.
CONCLUSION:
RFPDT appears to be an effective treatment method for CSC. ONL thickness is an important visual predictive factor of RFPDT for CSC.
AuthorsYasuhiro Ohkuma, Takaaki Hayashi, Tsutomu Sakai, Akira Watanabe, Hiroshi Tsuneoka
JournalGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (Graefes Arch Clin Exp Ophthalmol) Vol. 251 Issue 8 Pg. 1909-17 (Aug 2013) ISSN: 1435-702X [Electronic] Germany
PMID23456099 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Photosensitizing Agents
  • Porphyrins
  • Verteporfin
Topics
  • Adult
  • Aged
  • Central Serous Chorioretinopathy (diagnosis, drug therapy, physiopathology)
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Photochemotherapy
  • Photosensitizing Agents (therapeutic use)
  • Porphyrins (therapeutic use)
  • Prognosis
  • Retina (pathology)
  • Retrospective Studies
  • Subretinal Fluid
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Verteporfin
  • Visual Acuity (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: